SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?

Monaldi Arch Chest Dis. 2020 Dec 23;90(4). doi: 10.4081/monaldi.2020.1579.

Abstract

We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antiviral Agents / administration & dosage
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • COVID-19* / diagnosis
  • COVID-19* / physiopathology
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / immunology
  • Cystic Fibrosis* / physiopathology
  • Drug Combinations
  • Humans
  • Hydroxychloroquine / administration & dosage*
  • Lopinavir / administration & dosage*
  • Lung / diagnostic imaging
  • Lung / physiopathology
  • Male
  • Oxygen Inhalation Therapy / methods
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / etiology
  • Receptors, Interleukin-6 / antagonists & inhibitors
  • Respiratory Function Tests / methods
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / etiology
  • Respiratory Tract Infections / microbiology*
  • Ritonavir / administration & dosage*
  • SARS-CoV-2 / isolation & purification*
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Drug Combinations
  • Receptors, Interleukin-6
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • tocilizumab
  • Ritonavir